ENZN Key Stats
- ENZN July Options Begin Trading May 20
- Special Dividend and Ongoing Cash Distribution May 14
- Billionaire Seth Klarman's Long-Term Stock Picks May 13
- Seth Klarman's Worst Performing Stock Picks Year-To-Date May 13
- ENZON PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 10
- ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 6
- ENZON PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements... Apr 23
- Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $... Apr 23
- UPDATE: Enzon Reported Concluded Review of Possible Sale of Assets, Authorizes $... Apr 23
- Enzon concludes review of possible asset sale, sale of company, announces specia... Apr 23
ENZN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Enzon Pharmaceuticals is up 46.63% over the last year vs S&P 500 Total Return up 31.95%, Merck up 30.26%, and Vertex Pharmaceuticals up 29.52%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ENZN
Pro Report PDF for ENZN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ENZN Pro Report PDF
Pro Strategies Featuring ENZN
Did Enzon Pharmaceuticals make it into our Pro Portfolio Strategies?